By Mirianna la Grasta |
, a Belfast-based AI startup, has raised 鈧�1.2 million (拢1 million) to further develop, test and certify an AI cap that could help diagnose and monitor neurological disorders faster and more accurately.
The latest funding round was led by Par Equity, together with Techstart Ventures, Co-Fund II, Angel CoFund and British Business Investments, and it will support further developments in the technology, as well as bigger commercial activities and clinical trials.
The technology they have developed allows for the easy and remote home-assessment of both neurodegenerative diseases and psychiatric disorders. It connects a wireless headset to a series of gamified neurocognitive tests that can be played on a tablet, whose results and data will then be gathered on a cloud-based analytics platform.
More from News
- Two Thirds of Brits Are Telling AI Chatbots Their Secrets But Don’t Trust The Companies Behind Them
- Video Game Companies Are Abandoning “Buy Our Console To Play This” 鈥� Here鈥檚 Why
- UK Gambling Operators Face New Deposit Limit Rules From 30 September
- How A Ransomware Gang Hijacked A Rival Gang鈥檚 Website 鈥� And Is Now Extorting Them For “2.333% Of Their Net Worth
- Meta Promised Unmatched Privacy For Muse 鈥� So How Did Researchers Crack It So Quickly?
- Digital Avatars Are Bringing Deceased Artists Back To The Stage 鈥� Where Do We Draw The Line?
- Can Europe Solve Its Critical Minerals Problem Fast Enough To Support Its Tech Ambitions?
- Google Has Agreed To A 拢260 Million Settlement: Who’s Eligible For Compensation?
The neoprene device is a wearable electroencephalography (EEG) cap that measures and monitors, in a non-invasive way, the mechanisms that underpin neurological disorders and therapies.
While the BrainWaveBank platform offers secure gathering, storage and analysis of data from thousands of users, and it builds neurocognitive profiles for individuals, populations and different demographic groups.
The startup, which was founded in 2015, believes that the platform鈥檚 individual-level data could provide users with personalised insights into their cognitive health, while group-level figures could support clinical trials, as well as the development of new therapies and diagnostics worldwide.
BrainWaveBank is now developing brain-based biomarkers for different use-cases, like early detection of brain disorders, treatment-response-tracking and stratification of patient groups. At present, its clients include pharmaceutical and biotech companies, as well as university and teaching hospitals. The startup has recently secured a series of contracts with companies that would like to use the technology to gain insights into the effect of drugs during early-stage clinical evaluations of new therapies for Alzheimer鈥檚 disease and other psychiatric conditions.
